Celgene, Jounce in immuno-oncology deal

Celgene Corp. (NASDAQ:CELG) obtained options to license multiple immuno-oncology programs from Jounce Therapeutics Inc. (Cambridge, Mass.), including lead

Read the full 183 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE